20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Shares of Biofrontera (NASDAQ:BFRA) moved higher by 0.1% in pre-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share were flat 0.00% year over year to ($0.00), which beat the estimate of ($0.34).
Revenue of $5,508,000 declined by 1.98% from the same period last year, which missed the estimate of $5,900,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Biofrontera hasn't issued any revenue guidance for the time being.
Recent Stock Performance
Company's 52-week high was at $55.00
Company's 52-week low was at $5.27
Price action over last quarter: down 32.85%
Company Profile
Biofrontera AG is active in the field of healthcare in the United Kingdom. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!